BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23817684)

  • 1. Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer.
    Souvatzoglou M; Eiber M; Takei T; Fürst S; Maurer T; Gaertner F; Geinitz H; Drzezga A; Ziegler S; Nekolla SG; Rummeny EJ; Schwaiger M; Beer AJ
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1486-99. PubMed ID: 23817684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses.
    Drzezga A; Souvatzoglou M; Eiber M; Beer AJ; Fürst S; Martinez-Möller A; Nekolla SG; Ziegler S; Ganter C; Rummeny EJ; Schwaiger M
    J Nucl Med; 2012 Jun; 53(6):845-55. PubMed ID: 22534830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated whole-body PET/MR hybrid imaging: clinical experience.
    Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
    Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative and quantitative comparison of PET/CT and PET/MR imaging in clinical practice.
    Al-Nabhani KZ; Syed R; Michopoulou S; Alkalbani J; Afaq A; Panagiotidis E; O'Meara C; Groves A; Ell P; Bomanji J
    J Nucl Med; 2014 Jan; 55(1):88-94. PubMed ID: 24337608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective head-to-head comparison of
    Eiber M; Rauscher I; Souvatzoglou M; Maurer T; Schwaiger M; Holzapfel K; Beer AJ
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2179-2188. PubMed ID: 28803358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study to
    Zheng D; Liu Y; Liu J; Li K; Lin M; Schmidt H; Xu B; Tian J
    Cancer Imaging; 2020 Jun; 20(1):39. PubMed ID: 32546207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/MR imaging in the detection and characterization of pulmonary lesions: technical and diagnostic evaluation in comparison to PET/CT.
    Rauscher I; Eiber M; Fürst S; Souvatzoglou M; Nekolla SG; Ziegler SI; Rummeny EJ; Schwaiger M; Beer AJ
    J Nucl Med; 2014 May; 55(5):724-9. PubMed ID: 24652827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncological whole-body staging in integrated (18)F-FDG PET/MR: Value of different MR sequences for simultaneous PET and MR reading.
    Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Beiderwellen K; Ruhlmann V; Umutlu L; Quick HH; Antoch G; Buchbender C
    Eur J Radiol; 2015 Jul; 84(7):1285-92. PubMed ID: 25975895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
    Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
    Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Positron Emission Tomography Quantification Using Magnetic Resonance- and Computed Tomography-Based Attenuation Correction in Physiological Tissues and Lesions: A Whole-Body Positron Emission Tomography/Magnetic Resonance Study in 66 Patients.
    Seith F; Gatidis S; Schmidt H; Bezrukov I; la Fougère C; Nikolaou K; Pfannenberg C; Schwenzer N
    Invest Radiol; 2016 Jan; 51(1):66-71. PubMed ID: 26348596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen.
    Kuhn FP; Crook DW; Mader CE; Appenzeller P; von Schulthess GK; Schmid DT
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):44-51. PubMed ID: 22955547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.
    Turkbey B; Mena E; Shih J; Pinto PA; Merino MJ; Lindenberg ML; Bernardo M; McKinney YL; Adler S; Owenius R; Choyke PL; Kurdziel KA
    Radiology; 2014 Mar; 270(3):849-56. PubMed ID: 24475804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
    Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
    Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging prostate cancer with 11C-choline PET/CT.
    Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
    J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.